Literature DB >> 351203

Pathological growth of androgensensitive tissues resulting from latent actions of steroid hormones.

N Bruchovsky, P S Rennie, E V Doorn, R L Noble.   

Abstract

Hormonal responsiveness should be considered in terms of at least three homeostatic constraint mechanisms. Observations on the induction of specific responses in rat prostate reveal that certain of these are controlled differentially, and also that immature cells can be modified by low levels of androgen. The conditioning effect of low levels of steroid is further demonstrated by the benefits of fractional hormone-replacement therapy in controlling and delaying tumor progression. A revised approach to endocrine therapy of cancer should be seriously considered. This would entail the fractional replacement of hormone after ablative surgery.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 351203     DOI: 10.1080/15287397809529667

Source DB:  PubMed          Journal:  J Toxicol Environ Health        ISSN: 0098-4108


  5 in total

Review 1.  Systemic therapy of advanced breast cancer.

Authors:  H T Mouridsen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 2.  Patient-Clinician choice in palliation of metastatic prostate cancer.

Authors:  A V Kaisary
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

3.  Increased activity of plasminogen activators during involution of the rat ventral prostate.

Authors:  P S Rennie; R Bouffard; N Bruchovsky; H Cheng
Journal:  Biochem J       Date:  1984-07-01       Impact factor: 3.857

4.  Radioimmunoassay measurements of nuclear dihydrotestosterone in rat prostate. Relationship to androgen receptors and androgen-regulated responses.

Authors:  M A De Larminat; P S Rennie; N Bruchovsky
Journal:  Biochem J       Date:  1981-12-15       Impact factor: 3.857

5.  The relationship between inhibition of plasminogen-activator activity and prostatic involution.

Authors:  P S Rennie; J F Bowden; N Bruchovsky; H Cheng
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.